Viking Therapeutics (VKTX) is up more than +5% after the company’s experimental pill, VK2735, showed weight loss in patients at higher doses with limited side effects. Air Transport Services Group ...

Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and ...

Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.